Original Research

Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study

Published in: Volume 10 / Year 2021 / Issue 3
Page: 119-22

Author byline as per print journal: Pieter J Glerum1,2, MSc; Mert Hayta1,3, PharmD, MSc; David M Burger4, PharmD, PhD; Cees Neef5, PharmD, PhD; Marcel L Bouvy3, PharmD, PhD; Marc Maliepaard1,6,… Read More »

Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers

Published in: Volume 10 / Year 2021 / Issue 3
Page: 113-8

Author byline as per print journal: Nishalini Harikrishnan1, BSc; Ka-Liong Tan2, DPhil; Kar Ming Yee3, BPharm; Alia Shaari Ahmad Shukri1, MSc; Nalla Ramana Reddy4, MBBS; Chuei Wuei Leong3, PhD Introduction/Study… Read More »

Variation in the prices of oncology medicines across Europe and the implications for the future

Published in: Volume 10 / Year 2021 / Issue 2
Page: 72-82

Author byline as per print journal: Brian Godman1,2,3, BSc, PhD; Steven Simoens4, MSc, PhD; Amanj Kurdi1,5, BSc, PhD; Gisbert Selke6; John Yfantopoulos7, PhD; Andrew Hill8, PhD; Jolanta Gulbinovič9, MD, PhD;… Read More »

Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching

Published in: Volume 10 / Year 2021 / Issue 2
Page: 68-71

Author byline as per print journal: Mansour Somaily1, MD; Hana Alahmari1, MD; Wejdan Abbag2; Shahenda Yousif4, MD; Nawar Tayfour4, MD; Nouf Almushayt2; Saleh Alhusayni3, MD; Saeed Almajadiah4, MD Background: A… Read More »

Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector via simulation

Published in: Volume 10 / Year 2021 / Issue 2
Page: 61-7

Author byline as per print journal: Kelly Canham1, BSc Hons; Claire Newcomb2, MSc Introduction/Study Objectives: Etanercept is a tumour necrosis factor inhibitor indicated for the treatment of several inflammatory disorders.… Read More »

An assessment of trends in the Iranian pharmaceutical market following domestic production of selected medications (2007‒2017) and new considerations for health policymakers

Published in: Volume 10 / Year 2021 / Issue 1
Page: 33-43

Author byline as per print journal: Marzieh Zargaran1, PharmD, PhD Candidate; Abdol Majid Cheraghali 2,3, PharmD, PhD; Fatemeh Soleymani1,2, PharmD, MPH, PhD; Rajabali Daroudi4, BSc, MSc, PhD; Ali Akbari Sari4,… Read More »

Biosimilars – status in July 2020 in 16 countries

Published in: Volume 10 / Year 2021 / Issue 1
Page: 4-32, 41

Author byline as per print journal: Hye-Na Kang1, PhD; Robin Thorpe2, PhD, FRCPath; Ivana Knezevic1, PhD; Daehyun Baek3, PhD; Parichard Chirachanakul4; Hui Ming Chua5; Dina Dalili6, PhD; Freddie Foo7, MSc;… Read More »

Local policies on biosimilars: are they designed to optimize use of liberated resources?

Published in: Volume 9 / Year 2020 / Issue 4
Author(s): ,
Page: 163-70

Author byline as per print journal: Arianna Bertolani, PhD; Claudio Jommi, MS Study Objectives: Different policies have been implemented to enhance uptake of biosimilars. Regarding policies focussing on the demand-side,… Read More »

Physicochemical stability of the bevacizumab biosimilar, ABP 215, after preparation and storage in intravenous bags

Published in: Volume 9 / Year 2020 / Issue 4
Page: 155-62

Author byline as per print journal: Jolita Seckute1, PhD; Ingrid Castellanos2, PhD; Steven Bane1, PhD Study Objectives: To evaluate extended in-use stability of bevacizumab biosimilar, ABP 215, after dilution into… Read More »

Systematic analysis of injection-site pain and reactions caused by subcutaneous administration of the adalimumab biosimilar FKB327 versus the adalimumab reference product via different delivery methods

Published in: Volume 9 / Year 2020 / Issue 3
Page: 108-15, 96

Author byline as per print journal: Rieke Alten1, MD, PhD; Herbert Kellner2, MD; Malcolm Boyce3, MD; Takuma Yonemura4, MD; Takahiro Ito5, MSc; Mark C Genovese6, MD Introduction/Study objectives: FKB327 is… Read More »

Page 1 of 6 1 2 3 4 5 Next »... 6
Go Back Print